Xadago
·
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Safinamide
- Made by
- Zambon SpA
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Zambon SpA |
|---|---|
| Active substance | Safinamide |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N04B · Pain, sleep, mood, epilepsy and the brain |
| Authorised on | 2015-02-23 |
| Last updated by the regulator | 2026-02-09 |
| EMA product number | EMEA/H/C/002396 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).